Search

Your search keyword '"Bychenkova A"' showing total 4 results
Start Over Author "Bychenkova A" Publication Year Range Last 3 years
4 results on '"Bychenkova A"'

1. PRACTICAL ASPECTS OF THE CONVERGENCE OF EDUCATION AND BUSINESS ON THE EXAMPLE OF SPECIALISTES TRAINING IN THE SPHERE OF THE FOOD INDUSTRY

Author

Elena Chernova, Valerya Bychenkova, Natalia Barsukova, and Natalia Kotova

Subjects
образовательный процесс, информационные технологии, индустрия питания, технология продукции, организация производства и обслуживания, конвергенция, educational process, information technology, food industry, product technology, organization of production and service, convergence, Economics as a science, HB71-74
Abstract

The article discusses the convergence of education and business on the example of training bachelors and masters in the direction «Technology ofproducts and organization of catering::. The implementation of this approach is carried out using its own educational standards, developed taking into account the requirements of the Federal State Educational Standard in this direction and Professional Standards. This is reflected in the structure of the Educational Program, the choice of disciplines, as well as in the subject of final qualification works for students of the Graduate School of Biotechnology and Food Science of the Peter the Great St. Petersburg Polytechnic University, a number of which are presented in this article.

Published
2022

2. Economic Evaluations of Pharmacological Treatments in Heart Failure Patients: A Methodological Review with a Focus on Key Model Drivers

Author

Di Tanna, Gian, Chen, Shuxian, Bychenkova, Anna, Wirtz, Heidi, Burrows, Karen, and Globe, Gary

Abstract

Various decision analytic models exist for evaluating the cost-effectiveness of pharmacological interventions for heart failure (HF). Despite this, studies that explore drivers influencing these modeling approaches remain scarce. Through a systematic review of the literature, the present study sought to identify model drivers that emerge from economic evaluations of HF pharmacological interventions. Among the 72 cost effectiveness papers evaluating HF drug interventions, the most frequently identified, top 5 ranked model drivers impacting the incremental cost-effectiveness ratio (ICER) were cost of treatment and utility, identified in 10% of studies, respectively. Other drivers that emerged as top 5 ranked drivers in > 5% of studies included treatment effect on mortality (or cardiovascular mortality), duration of treatment, and baseline cardiovascular mortality. Model drivers reported at the top of tornado diagrams were treatment effect on mortality or on cardiovascular mortality. Collectively, these observations highlight the key importance of treatment effect in driving cost-effectiveness models for HF.

Published
2024
Full Text
View/download PDF

3. Dynamics of humoral immunity to SARS-CoV-2 in the professionally homogeneous group of people over a two-year period of COVID-19 outbreak

Author

VG Pomelova, TA Bychenkova, NI Bekman, NS Osin, YuN Ishkov, and KK Styazhkin

Abstract

It is important to control the levels of specific IgG against SARS-CoV-2 to ensure the timely monitoring of immunity in patients with COVID-19. Yet it is unclear what antibody levels protect against new infection and how long the protection is maintained. The study was aimed to assess the dynamic changes in the levels of IgG against SARS-CoV-2 by the two-year controlled observation. Healthy individuals (n = 70), COVID-19 survivors (n = 42), and people vaccinated with Sputnik V (n = 43) were enrolled. They were followed-up from April 2020 to April 2022. Serum IgG levels were defined (n = 312) using immunochip and the commercially available test system. Significance of differences was estimated using the Mann–Whitney U test for р ≤ 0.05. IgG levels in the disease survivors (median 97.1; 95% CI: 80–162 BAU/mL) and vaccinated individuals (103.1; 78–139 BAU/mL) were significantly higher than in healthy people (4.3; 4.1–4.5 BAU/mL). Intensity of immune response significantly increased after vaccination of the disease survivors (up to 1023; 657–1191 BAU/mL) or administration of booster dose to vaccinated individuals (413; 213–545 BAU/mL). In elderly convalescents (60+), IgG levels were significantly higher, and in vaccinated people these were significantly lower, than in people under the age of 60. IgG levels decreased faster in vaccinated individuals (after 3–4 months), than in the disease survivors, and stabilized at

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results